Fennec Pharmaceuticals (FENC) News
NASDAQ: FENCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
13.09-0.36 (-2.68%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FENC news summary
We found 4 recent headlines mentioning Fennec Pharmaceuticals (FENC): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, FENC is down 2.68% at $13.09. The most recent story, "Fennec Pharma (FENC) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Fennec Pharmaceuticals headlines
- Fennec Pharma (FENC) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Fennec Pharmaceuticals Swings To Profit In Q3 On Surging PEDMARK Sales; Stock Up(RTTNews) - Fennec Pharmaceuticals Inc. (FENC, FRX.TO) released third-quarter results, reporting a swing to net profitability driven by a 56% surge in PEDMARK product sales.NasdaqFENC, BF.A
- Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~GlobeNewswire
- Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the…GlobeNewswire